Dosinda Cohn

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

Pharmacy, Pharmacotherapy, Bone Metabolism +10

Once-weekly dose of 8400 IU vitamin D3 compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency

Paul Lips, Neil Binkley, Michael Pfeifer et al. · American Journal of Clinical Nutrition · 2010 · 116 citations

Medicine, Geriatric Medicine, Pharmacotherapy +15

Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension

Robert R. Recker, David W. Dempster, Bente Langdahl et al. · Journal of Bone and Mineral Research · 2020 · 29 citations · Full text

Medicine, Pharmacotherapy, Bone Metabolism +16

In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism.

Thomayant Prueksaritanont, Polly DeLuna, Lynn M. Gorham et al. · PubMed · 1998 · 26 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial

Socrates E. Papapoulos, Henry G. Bone, Felicia Cosman et al. · Journal of Bone and Mineral Research · 2020 · 26 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17